STAT June 21, 2024
Adam Feuerstein

Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration expanded approval of the company’s Duchenne muscular dystrophy drug on Thursday. Will boys with Duchenne also benefit? I hope they do, but it’s uncertain. And is this a good look for the FDA? No, it is not.

There is much to unpack from the unilateral decision by Peter Marks, the FDA’s top regulator of gene...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
NIH Launches myeloMATCH Precision Medicine Trials for Myeloid Cancers
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
FDA approves 1st RSV vaccine for adults under 60
Lawmakers seek answers on Pfizer, Lilly telehealth moves
Can Herbal Alternatives Ease the Economic Burden of Weight Loss Drugs?

Share This Article